MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

529.91 1.37

Buy Sell

Overview

Share price change

24h

Current

Min

519.87

Max

539.08

Key metrics
By Trading Economics
Income	56M -59M
Sales	34M 321M
Profit margin	-18.243
Employees	915
EBITDA	56M -50M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+34.66% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1B 12B
Previous open	528.54
Previous close	529.91

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 kwi 2026, 22:56 UTC

Major News Events

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 kwi 2026, 20:50 UTC

Acquisitions, Mergers, Takeovers

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 kwi 2026, 23:55 UTC

Market Talk

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 kwi 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 kwi 2026, 23:23 UTC

Major News Events

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 kwi 2026, 23:07 UTC

Earnings

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 kwi 2026, 23:02 UTC

Major News Events

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 kwi 2026, 22:39 UTC

Earnings

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 kwi 2026, 22:08 UTC

Market Talk

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 kwi 2026, 22:00 UTC

Major News Events

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 kwi 2026, 22:00 UTC

Major News Events

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 kwi 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 kwi 2026, 21:31 UTC

Major News Events

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 kwi 2026, 20:38 UTC

Earnings

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 kwi 2026, 20:31 UTC

Acquisitions, Mergers, Takeovers

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 kwi 2026, 20:16 UTC

Acquisitions, Mergers, Takeovers

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 kwi 2026, 20:16 UTC

Acquisitions, Mergers, Takeovers

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 kwi 2026, 20:13 UTC

Acquisitions, Mergers, Takeovers

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 kwi 2026, 20:07 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 kwi 2026, 20:07 UTC

Acquisitions, Mergers, Takeovers

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

34.66% upside

12 Months Forecast

Average 704.88 USD 34.66%

High 964 USD

Low 529 USD

Based on 10 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.